Arrowhead Pharmaceuticals Inc. (ARWR) announced after the bell Tuesday that it will discontinue development of clinical stage drug candidates ARC-520, ARC-521 and ARC-AAT. The company will also reduce its workforce by about 30 percent.
from RTT - Before the Bell http://ift.tt/2gJwY8g
via IFTTT
No comments:
Post a Comment